What is the dosage and treatment duration of Meropenem (antibiotic) for severe bacterial infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Meropenem Dosing and Treatment Duration for Severe Bacterial Infections

For severe bacterial infections, administer meropenem 1 gram IV every 8 hours via extended infusion over 3 hours, with treatment duration of 5-7 days based on clinical response and source control adequacy. 1, 2

Standard Dosing Regimens

Adult Patients with Normal Renal Function

  • Complicated intra-abdominal infections: 1 gram IV every 8 hours 3
  • Complicated skin and soft tissue infections: 500 mg IV every 8 hours (standard) or 1 gram IV every 8 hours when Pseudomonas aeruginosa is suspected or documented 3, 4
  • Carbapenem-resistant Enterobacteriaceae (CRE) infections: 1 gram IV every 8 hours by extended infusion (3 hours) as part of combination therapy 1, 2
  • Carbapenem-resistant Acinetobacter baumannii (CRAB): 2 grams IV every 8 hours when MIC ≤8 mg/L, as part of combination therapy 1

Administration Method

  • Standard infusion: 15-30 minutes for routine infections 3
  • Extended infusion: 3 hours when MIC ≥8 mg/L or for CRE infections to optimize pharmacodynamic targets 1, 2
  • Bolus injection: 3-5 minutes for doses up to 1 gram (acceptable alternative) 3
  • No loading dose required for meropenem, unlike colistin or tigecycline 1

Pediatric Dosing

Children ≥3 Months of Age

  • Complicated skin/soft tissue infections: 10 mg/kg every 8 hours (maximum 500 mg per dose) 3
  • Complicated intra-abdominal infections: 20 mg/kg every 8 hours (maximum 1 gram per dose) 3
  • Bacterial meningitis: 40 mg/kg every 8 hours (maximum 2 grams per dose) 3
  • For children >50 kg, use adult dosing 3

Infants <3 Months of Age (Complicated Intra-abdominal Infections Only)

  • <32 weeks gestational age (GA) and <2 weeks postnatal age (PNA): 20 mg/kg every 12 hours 3
  • <32 weeks GA and ≥2 weeks PNA: 20 mg/kg every 8 hours 3
  • ≥32 weeks GA and <2 weeks PNA: 20 mg/kg every 8 hours 3
  • ≥32 weeks GA and ≥2 weeks PNA: 30 mg/kg every 8 hours 3

Renal Dose Adjustments

Dosing must be reduced when creatinine clearance falls below 50 mL/min: 3

  • CrCl 26-50 mL/min: Standard dose every 12 hours 3
  • CrCl 10-25 mL/min: Half the standard dose every 12 hours 3
  • CrCl <10 mL/min: Half the standard dose every 24 hours 3
  • Inadequate data exists for hemodialysis or peritoneal dialysis patients 3

Treatment Duration

The Infectious Diseases Society of America recommends 5-7 days for most complicated infections, individualized based on: 1, 2

  • Adequacy of source control (surgical drainage, debridement) 1
  • Clinical response to therapy 1, 2
  • Resolution of fever and leukocytosis 1
  • For cholecystitis with cholecystectomy: Discontinue within 24 hours if no infection extends beyond the gallbladder wall 1

Optimization Strategies for Resistant Organisms

When to Use Extended Infusion

Extended 3-hour infusion is critical when: 1, 2

  • Treating CRE infections 1, 2
  • MIC ≥8 mg/L for the causative pathogen 1, 2
  • Critically ill patients with healthcare-associated infections 2

Combination Therapy Considerations

  • CRE bloodstream infections: Meropenem 1 gram IV every 8 hours (extended infusion) plus a second active agent based on susceptibility testing 5, 2
  • CRAB infections: High-dose meropenem (2 grams every 8 hours) plus colistin when meropenem MIC ≤8 mg/L 1
  • Newer agents preferred as monotherapy when susceptible: meropenem-vaborbactam 4 grams IV every 8 hours for KPC-producing CRE 1, 2

Common Pitfalls to Avoid

  • Do not combine meropenem with piperacillin-tazobactam: This represents redundant beta-lactam coverage that violates antimicrobial stewardship principles 6
  • Meropenem lacks activity against: MRSA and VRE—add vancomycin or linezolid if these pathogens are suspected 1
  • Do not use standard infusion times for resistant organisms: Extended infusion is essential for adequate time above MIC when treating organisms with MIC ≥8 mg/L 1, 2
  • Adjust for renal function: Failure to reduce dosing in renal impairment increases seizure risk 3

Spectrum of Activity

Meropenem provides broad coverage against: 7, 8

  • Methicillin-susceptible Staphylococcus aureus (not MRSA) 1, 7
  • Streptococci and enterococci (vancomycin-susceptible only) 3, 8
  • Gram-negative pathogens including Pseudomonas aeruginosa 7, 8
  • ESBL-producing and AmpC-producing Enterobacteriaceae 7, 9
  • Anaerobes including Bacteroides fragilis 3, 8

References

Guideline

Meropenem for Complicated Bacterial Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Carbapenem-Resistant Enterobacteriaceae Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Meropenem in the treatment of complicated skin and soft tissue infections.

Therapeutics and clinical risk management, 2006

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Compatibility and Safety of Meropenem and Piperacillin-Tazobactam Combination

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.